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Context: The prevalence of Multiple Sclerosis (MS) in the world has grown 
and has attracted particular attention on the international level and 
governments, has considered prevention interventions and managing the 
symptoms of the disease to reduce the economic burden and has improved the 
quality of life of these patients necessary. One of the most important strategies 
in this field is MS population-based registry. Accordingly, this study was 
designed to identify the components of MS population-based registries within 
the developed countries. 
Evidence Acquisition: The present study is a review article that was conducted 
in 2018. The population of the study consisted of MS population-based registry 
systems of developed countries such as USA, France, and Denmark. Based on 
the combination of related keywords, about 60 papers appropriately and after 
extraction, categorization and integration were formulated in the form of proper 
sequence for the purpose of the study. 
Results: The main components of MS population-based registries in developed 
countries included registry goals, information resources, Minimum Data Sets 
(MDS), types of processes, types of reports, quality control measures, data 
transmission time limits, responsible for recording and collecting data, 
responsible organization and executor, data transmission method and the 
privacy practices 
Conclusion: With regard to the results, it is suggested that the developing 
countries must consider creating an MS population-based registry as a national 
program due to their health system and the MS population-based registries 
structure in developed countries, so that they can adopt a suitable strategy for 
preventing and controlling the disease. 
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     Multiple sclerosis (MS) is one of the 
human’s chronic neurological diseases; it is 
among one of the most common reported 
diseases, leading to disability in young 
adults, which appears by formation of 
multiple small and large plaques in the 
white matter of the brain and spinal cord [1-
3]. 
Across the world, the prevalence of this 
disease has grown increasingly, and there 
has been a special attention toward MS at 
the international level [4]. The prevalence 
of this disease among women is 1.77 
compared with men [3] and the most 
prevalence are between the ages of 20 to 40 
years [5, 6]. It has multiple complications 
such as visual problems, anal sphincter 
dysfunction, speech disorders, epilepsy, and 
depression [7-9]. Consequently, MS reduces 
the life expectancy up to between 8 to 10 
years [7]. 
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People with debilitating and chronic MS 
disease encounter many challenges such as 
physical, psychological, social and 
economic ones that limit their participation 
in health promotion activities and thus 
increase further complications, cause more 
limitations in their daily activities and also 
reduce their quality of life [10]. 
Therefore, MS imposes a lot of economic 
burden to patients, the society and the 
healthcare system [10]; therefore, the 
governments all over the world must pay 
attention to preventing of interventions and 
symptom management as to improve the 
patient’s quality of life [11]. Achievement 
of prevention goals, screening and disease 
control programs in the healthcare system is 
possible through complete and timely data 
collections of MS. There are many 
strategies for disease prevention and 
control, among which one of the most 
important is the disease registry [12].  
Registries could provide complete, accurate, 
and high-quality data [13] and have been 
established for different health problems 
and diseases with different purposes [14, 
15], designed in two types, including 
hospital-based registries and population-
based registries [16]. The population-based 
registry is an organized process for 
collecting, recording, retrieving, and using 
information from patients who have a 
particular disease and live in a specific 
geographical area [12, 17, 18]. The use of 
these registries in the healthcare systems 
has led to many improvements in various 
areas, including providing services and 
patient care [19]. The MS population-based 
registry is beneficial in terms of managing 
and controlling the symptoms of a large 
population with MS disease, monitoring the 
outbreak and prevalence of the disease, 
providing effective information on the 
safety and efficacy of MS treatment and 
drugs [20, 21], providing an important 
guidance to the decision making of both 
clinical and socioeconomic groups, and help 
to better understanding of the disease 
process, quality of life, mortality, and 
complications of MS [22]. 
The existence of this type of registry 
facilitates the sampling methods in clinical 
trials across the country, and consequently 
reduces cost and time [23]. In addition, it 
has an effective role in improving the 
quality of healthcare [20, 21], and some 
useful information can be provided in terms 
of age, gender, and the geographical 
distribution of MS patients [24]. Therefore, 
considering the benefits and goals, 
designing population-based MS registry is 
of utmost importance. 
Given the fact that the United States and 
European countries, including France, 
Denmark, and so forth have been pioneer in 
establishing the population-based MS 
registry, and have made a significant 
progress in developing this system, the 
present study aimed to introduce the 
instructions and experiences of the MS 
population registry in these developed 
countries for the use within developing 
countries. 
 
2. Evidence Acquisition 
     In this review article, the population-
based MS registries of the US, France and 
Denmark were reviewed. These countries 
were selected due to their leading role in the 
population-based registries. Related articles 
were extracted from databases including 
PubMed, Google Scholar, Springer, Science 
Direct and Wiley, with the following key 
keywords or a combination of them: 
multiple sclerosis; registry; population 
registry; multiple sclerosis population-based 
registry.  
After a comprehensive search that was done 
based on the keywords, 110 articles were 
identified in 1998 to 2016. After the first 
review, 60 articles were considered based 
on the study objectives. To be included the 
articles in this review, studies were required 
to be related to the study purpose. The 
articles were carefully considered, and after 
extracting        information, they           were  
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categorized and integrated in the 
appropriate sequences to meet the needs of 
this study. 
 
3. Results            
     There are different titles for the multiple 
sclerosis population-based registries in the 
developed countries. Most of the registries 
collect the main demographic data, the 
period of disease, disability, medication, 
hospitalization, and test results. They are, 
however, different in goals, content, data 
structure, data architecture, time, and the 
used resources [6, 25]. Each country’s 
system, and state the systems similarities 
and differences in each country is described 
as follows. 
 
3.1 The Multiple Sclerosis Population-
Based Registry in the US 
     The US MS population-based registry is 
NARCOMS (The North American Research 
Committee on Multiple Sclerosis), which 
was created by the Consortium of Multiple 
Sclerosis Centers (CMSC) in 1993, for the 
purpose of developing patient-based MS 
registry and facilitating involvement of 
researchers from participating centers of 
MS treatment and research community [26, 
27]. 
NARCOMS is a global registry system for 
research on MS, treatment and patient 
education [23]. The secret of NARCOMS’ 
is its updated data which is obtained 
through collaborating and supporting of a 
number of organizations including the 
Multiple Sclerosis Consortium, the National 
Multiple Sclerosis Society (NMSS), the 
Paralyzed Veterans of America (PVA), and 
the Eastern Paralyzed Veteran’s Association 
(EPVA) [5]. 
The registry data includes demographic and 
clinical data [26, 28]. Statistical analysis of 
the data was done by the official review 
committee of the registry, at the University 
of Alabama. The conducted results from 
this registry is usually published in 
scholarly journals and shared with 
participants through NARCOMS quarterly 
journal [5]. 
Therefore, NARCOMS is one of the largest 
voluntary registry systems in the world, 
which provides extensive studies in the 
areas of MS research field [5]. 
 
3.2 EUReMS: European Registry for 
Multiple Sclerosis 
     The European MS registry is a central 
data source of various aspects of MS. The 
four key areas of this registry include 
epidemiology, the result of long-term 
treatment, healthcare issues and quality of 
life [29]. 
Currently, many European countries use the 
national registry of MS and other databases, 
including the Danish Multiple Sclerosis 
Registry (DMSR) and the European 
Database Multiple Scleroses (EDMUS). 
 
3.3 The MS Database in France 
     EDMUS is a widespread clinical 
database at the French MS centers that has 
been available since 1992 [25]. The 
database is organized by the European 
Union and supported by the international 
associations. EDMUS provides a brief 
descriptive record for research purposes, as 
well as assessment, quality assurance, 
classification, and preserving confidentiality 
of the data [30].  The EDMUS registry 
developer, developed a software with the 
same name to collect data from medical 
centers and management of MS patient 
records. This is a web based registry 
software, that is accessible through internet, 
and its ability to send data to international 
registries make it easier to perform [29]. 
In fact, EDMUS is a descriptive registry 
with a necessary minimum data set, which 
is used for research purposes in clinical and 
laboratory data documents among patients 
with multiple sclerosis [25]. The data that 
entered the international registry through 
EDMUS are included in the 10 main 
categories [29]. 
In this system, many considerations have 
been taken to preserve confidentiality of the 
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data, and to access the software and files, 
with specific passwords defined for 
different levels [25]. It is worth mentioning 
that it can be shared on the network and 
used as a multi-user software. The data is 
also searchable based on different criteria in 
the database, and could be cleaned to detect 
or correct incomplete, inconsistent and 
incorrect data [31]. 
Therefore, EDMUS is a powerful database 
for registering MS patients in Europe with 
the aim of medical treatment and scientific 
research [25]. 
 
3.4 The Population Registry of 
Multiple Sclerosis in Denmark 
     In Denmark, there are two population-
based MS registries. The older one is the 
DMSR (the Danish Multiple Sclerosis 
Registry), an epidemiological registry for 
estimating MS incidence and prevalence, 
patients’ survival, and identifying high-risk 
cases. This registry does not provide a 
systematic follow up for patients [32]. 
The DMSR was officially established in 
1956, but data collection began from 1948. 
Initially, the American MS association was 
in charge of it, and later, the MS association 
of Denmark [20, 33]. 
The diagnostic criteria, until 1994, were 
based on Allison and Millar (a set of 
clinical criteria for the diagnosis of MS). 
From 1994, the diagnostic criteria were 
those of Poser, and McDowell criteria have 
been considered for diagnosis since 2005 
[32, 34]. 
According to the regulations and rules of 
the data inspection office and in accordance 
with certain exceptions to the data security 
and privacy laws, there is no need for 
informed consent from the patient, provided 
that the data are stored in accordance with 
the confidentiality rules, and the data, with 
or without indicating the individual's 
identity can never be used for any other 
purposes of pure science [32]. 
Other Danish MS registry was Danish MS 
treatment registry that was established in 
1996, sponsored and developed by the 
Danish safety association. In practice, this is 
a registry for following all MS patients who 
received health care services since 1996, 
and are followed every six months by 
neurological and reliable laboratory tests 
[32]. 
The data reported to the MS registry include 
primary clinical information and follow-up, 
recurrence of disease, disability status, MRI 
results, disease progression and side effects 
during treatment [32]. These data are stored 
on-line from all sites into a central database. 
The registry imports the collected data to 
the DMSR. The criteria for importing data 
are the same criteria for treatment (currently 
McDonald) that are evaluated by three 
neurologists [32, 34] . 
Finally, the reports from the research, such 
as the relationship between MS and 
genetics, the environment, age, sex, 
pregnancy complications, and other factors 
are presented for therapeutic analyses, 
identifying and controlling the high-risk 
cases, as well as identifying the prevalence 
rate by sex [32]. 
Based on the above-mentioned statements, 
the main components of the MS population-
based registries in the United States, France 
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Table 1. the main components of the MS population register 
America France Denmark Component/countries 
treatment and education of MS 
patients, Medical research 
 
 
treatment and education of MS patients 
Medical research 




The registry goals 
Patients’ self-report data  Hospital-based registries 
Medical centers 
MS association 
MS research centers 
Rehabilitation and neurological 
departments in hospitals, General 
practitioners, Central disability 
insurance court, Neurological 
centers, Doctors specializing in MS 
neurology, MS association 
Data resources 
Demographic data (age, sex, race, 
etc.), and Clinical data (age of onset 
of symptoms, age of diagnosis, 
relapse date, etc.) 
Personal data, history, diagnosis, 
nervous events, irreversible disabilities, 
medical evaluations, paraclinical 
evaluations, treatments, summary, and 
chart 
 
Demographic data (age, sex, place of 
living, etc.), and Clinical data (age of 
onset of symptoms, age of diagnosis, 
diagnostic criteria, information of 
the patient’s family, injury or 
disability status, treatments, relapse 
date, disability status, MRI outcome 
and side effects during treatment) 
Data elements 
Calculation of correlation 
coefficient (correlation evaluation 
and the relation between registry 
variables), Calculation of Bland-
Altman plot (to analyze the 
agreement between two parameters, 
for example, comparing two 
clinical measures to evaluate care 
patterns) 
 
Data processing using descriptive 
statistics 
Classification (encoding) data related 
to care and treatment and ECGPMS 
 
Data processing using descriptive 
statistics such as mean and logistic 
regression to calculate odds ratio 
Types of data processing 
 
The reports from the research, such 
as: 
prevalence rate, the relationship 
between MS and genetics, age of 
onset of symptoms, age of 
diagnosis   
Providing reports based on the doctors 
need for medical analyses, such as: 
results of treatments, and a variety of 
disabilities in MS patients 
 
The reports from the research, such 
as: 
prevalence rate, the relationship 
between MS and genetics, age, sex, 
and pregnancy complications, report 
of high-risk cases, prevalence rate 
among women, and men in the 
society  
Report types 
through the questionnaire and the 
NARCOMS form prevents the 
entry of unnecessary, incorrect, and 
inconsistent data 
EDMUS software classified the data 
automatically, and the data is also 
searchable based on different criteria in 
the database, and could be cleaned to 
detect or correct incomplete, 
inconsistent and incorrect data 
The entry of duplicate record is 
prevented by ID, and the data are 
evaluated by 3 neurologists 
Data quality criteria 
Communication and follow-up 
patients via email; for those who 
are not responsive to their emails 
through telephone number 
Active and inactive follow-up 
Active and inactive follow-up by 
neurologists 
Through link to other registries, 
including Danish registry office, 
follow-up patients in the Danish MS 
registry is done via ID (Identification 
Number),Active and inactive follow-
up 
Follow-up patients 
Every 6 months At least once a year Every 6 months The time interval for 
sending data 
With collaboration and support of 
CMSC, NMSS, PVA, EPVA 
A coordinated European action 
committee under the auspices of the 
European Union 
The Denmark MS association The responsible and 
executer organization 
patients Neurologists Neurologists The person who is 
responsible for 
recording and collecting 
data in the registry 
Online and complete the 
questionnaire form 
Online and complete the questionnaire 
form 
Online and complete the 
questionnaire form 
Sending data method 
Regulate data disclosure policies 
Assign unique identity to each 
patient, Assign password for 
providing information 
 
Regulate data disclosure policies 
Assign unique identity to each patient, 
Assign password for providing 
information 
 
Regulate data disclosure policies 
Assign unique identity to each 
patient, Assign password for 
providing information, Regulate data 
protection policies, Prohibition of 
using the data for other purposes  
Confidentiality and 
privacy methods 
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4. Conclusion 
     The review of population-based MS 
registries in selected countries demonstrates 
that MS is considered as a significant 
national health status.  
Henricksen, in a study entitled "Using the 
MS registry in epidemiological studies", 
introduced the role of Danish MS registry, 
and stated that using it in exploring the risk 
factors for MS outbreak and prevalence 
population-based MS registry is an effective 
tool for epidemiological studies of the 
disease [20]. In another study, entitled 
"Evaluation of usability and limitations of 
the Danish MS registry", done by Mason 
et.al, the importance of accuracy and 
precision of MS registry data sources was 
reviewed, due to its widespread use in 
research [35]. In 2015, Mayer et.al 
conducted a study entitled "Biobank and the 
Norwegian MS registry" to investigate MS 
risk factors. In this regard, he used MS 
registry and MS Bio-Bank for systematic 
collection of clinical and epidemiological 
data and biological samples [36]. 
The study of population-based MS registries 
in different countries, including the United 
States, France and Denmark, showed that 
these countries have designed their 
registries based on their healthcare system. 
Improving the quality of patient care, 
identifying the risk factors, monitoring the 
disease outbreak and prevalence and 
comprehensive guide to disease 
management are the most important goals 
of population-based MS registries within 
the selected countries. The NARCOMS 
registry is a patient-based registry, while the 
EDMUS and DMSR are physician-based 
registries. 
The study of the data resources in France 
and Denmark showed that hospitals, 
neurological centers, general practitioners, 
neurologists and MS associations are the 
main data sources for the population-based 
MS registry across the most of the 
developed countries. In the United States, 
however, the population-based registry 
relies on patients’ self-reported data. 
Another feature of the registry is the 
minimum data set (MDS), which is used to 
monitor the disease outbreak and 
prevalence, develop educational programs, 
and assess high-risk areas. In fact, most of 
global advanced registries and data 
collection facilitate reaching to these goals. 
In the population-based registries of the 
selected countries, the data included 
demographic and clinical data. 
The results of the study showed that in three 
selected countries, the reports are based on 
the need of physicians, other authorized 
individuals and organizations as to conduct 
medical analyses and to guide clinical and 
socio-economic groups. 
In the United States, data quality control is 
carried out through the questionnaire by 
using the NARCOMS form, which prevents 
the entry of unnecessary, incorrect, and 
inconsistent data. The entry of duplicate 
record is prevented in France through the 
EDMUS software and in Denmark through 
link to other registries, including Danish 
registry office, and using the identification 
numbers. Patient follow-up was done in all 
three countries. In DMSR registry, the 
patients follow up data is not recorded with 
regard to this point, and the clinical follow 
up is impossible for all patients. In the 
reviewed countries, data are recorded based 
on the confidentiality rules. In the United 
States and France, collecting information 
from patients can be done through obtaining 
informed consent, but in Denmark, there is 
no need for informed consent, provided that 
the data is stored and retrieved in 
accordance with the confidentiality rules.  
The study of population-based MS registry 
in progressed countries showed that this 
registry can be used as a useful tool for 
physicians to provide high-quality care, for 
patients to promote self-care, and for 
authorities to monitor the disease outbreak 
and prevalence. Therefore, developing 
countries, according to their healthcare 
system should consider establishing 
population-based MS registry as a national 
program, and through its implementation 
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and maintenance, adopt an appropriate 
strategy for controlling and preventing MS. 
In addition, the designing and developing of 
a registry needs providing appropriate 
infrastructure, equipment, deployment 
location, and appointing the MS registry 
executive officers. Considering these 
features would help developing countries to 
establish population-based MS registry, and 
also prevent possible problems. 
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